Chang, Ting-Tsung

Publishing since 1982 (Dinosaur)

Has published 140 publications in 29 years

Number of publications published per year by Chang, Ting-Tsung. (Source : PubMed)

Distribution of publications types for Chang, Ting-Tsung. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Huang CH, Kuo PL, Hsu YL, Chang TT, Tseng HI, Chu YT, Kuo CH, Chen HN, Hung CH. The Natural Flavonoid Apigenin Suppresses Th1- and Th2-Related Chemokine Production by Human Monocyte THP-1 Cells Through Mitogen-Activated Protein Kinase Pathways.  J Med Food  2010  
•  Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.  Hepatology  2010;51;2  
•  Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.  J. Viral Hepat.  2010;17;1  
•  Su WW, Chen CH, Lin HH, Yang SS, Chang TT, Cheng KS, Wu JC, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Lu SN. Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas.  Hepatology international  2009;3;4  
•  Chang TT. On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48.  Hepatology international  2009;3 Suppl 1  
•  Wu IC, Lai CL, Han SH, Han KH, Gordon SC, Chao YC, Tan CK, Sievert W, Tanwandee T, Xu D, Neo BL, Chang TT. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.  Hepatology  2009  
•  Chang TT, Chao YC, Gorbakov VV, Han KH, Gish RG, de Man R, Cheinquer H, Bessone F, Brett-Smith H, Tamez R. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.  J. Viral Hepat.  2009;16;11  
•  Yu YL, Chen IH, Shen KY, Huang RY, Wang WR, Chou CJ, Chang TT, Chu CL. A triterpenoid methyl antcinate K isolated from Antrodia cinnamomea promotes dendritic cell activation and Th2 differentiation.  Eur. J. Immunol.  2009;39;9  
•  Wang CS, Yao WJ, Chang TT, Wang ST, Chou P. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses.  Cancer Epidemiol. Biomarkers Prev.  2009;18;7  
•  Tseng KC, Chen LH, Chen CY, Chang TT, Chou AL, Wu IC, Cheng PN. Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b.  Hepatol. Res.  2009;39;6  

[ See timeline ] [ See all publications ]